Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.50 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7864711 | 1.00 | NPC1 (0.61) | NPC1KMT2AALDH1A1LMNANR1H4 | |
| SCHEMBL13229299 | 0.88 | NPC1 (0.59) | NPC1KMT2AALDH1A1LMNANR1H4 | |
| SCHEMBL13229362 | 0.88 | NPC1 (0.59) | NPC1KMT2AALDH1A1LMNANR1H4 | |
| SCHEMBL3889350 | 0.87 | ALDH1A1 (0.57) | NPC1KMT2AALDH1A1LMNANR1H4 | |
| SCHEMBL3889347 | 0.87 | ALDH1A1 (0.57) | NPC1KMT2AALDH1A1LMNANR1H4 | |
| SCHEMBL7866401 | 0.86 | LMNA (0.56) | NPC1KMT2AALDH1A1LMNAHTT | |
| SCHEMBL3895800 | 0.86 | LMNA (0.56) | NPC1KMT2AALDH1A1LMNAHTT | |
| SCHEMBL13042147 | 0.83 | KMT2A (0.60) | NPC1KMT2AALDH1A1LMNANR1H4 | |
| SCHEMBL4784087 | 0.83 | NPC1 (0.51) | NPC1KMT2AALDH1A1LMNAHTT | |
| SCHEMBL13229283 | 0.82 | NPC1 (0.59) | NPC1KMT2AALDH1A1LMNANR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476764-B2 | Phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-13 | — | — | US | disclosed |
| US-20070032470-A1 | Novel phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032470-A1 | Novel phenylcarboxyamides as beta-secretase inhibitors | BACE1, APP, BACE2 | NPC1 553/4885KMT2A 2775/4885ALDH1A1 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.